Medicinal Chemistry of Mid-sized Molecules on Biologically Active Peptides

DOI Web Site Web Site 33 References

Bibliographic Information

Other Title
  • ペプチド化学を利用した生体分子からの中分子創薬
  • ペプチド カガク オ リヨウ シタ セイタイ ブンシ カラ ノ チュウ ブンシソウヤク

Search this article

Description

Neuromedin U (NMU) displays various physiological activities including an anorexigenic effect, and the C-terminal heptapeptide-amide sequence is necessary to activate two NMU receptors (NMUR1 and NMUR2). Based on this heptapeptide, we recently developed highly active NMUR1 hexapeptide agonist 4d and NMUR2-selective hexapeptide agonist 8c. Moreover, we identified two major biodegradation sites (Phe2-Arg3 and Arg5-Asn6) by the stability analysis of 4d in serum. On the other hand, myostatin is an endogenous negative regulator of skeletal muscle mass, which is recognized as a therapeutic target for muscle atrophic disorders. Recently, we successfully identified myostatin inhibitory peptides 9 and 16 (24 and 23 amino acids, respectively) with minimum sequence derived from mouse myostatin prodomain. These peptides directly bind to myostatin with KD values of 30-36 nM. Moreover, peptide 9 significantly increased tibialis anterior muscle mass in Duchenne muscular dystrophy model mice. Therefore, these synthesized peptides would be promising mid-sized molecules for peptide-based medicinal chemistry.

Journal

References(33)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top